{"filing":{"accession_number":"0001213900-26-093979","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-26","report_date":"2026-08-21","primary_document":"ea0303509-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026093979/ea0303509-8k_jasper.htm"},"events":[{"id":29763,"run_id":27264,"accession_number":"0001213900-26-093979","anchor_item_number":"1.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, that it no longer satisfies the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within an extended period. This is a direct delisting risk disclosure under Item 1.01.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-08-26","form":"8-K","submitted_at":null,"items":[{"id":32146,"accession_number":"0001213900-26-093979","item_number":"1.01","item_title":"Notice of Delisting or Failure to Satisfy a","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, that it no longer satisfies the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within an extended period. This is a direct delisting risk disclosure under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T20:20:07.614474+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32146,"accession_number":"0001213900-26-093979","item_number":"1.01","item_title":"Notice of Delisting or Failure to Satisfy a","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, that it no longer satisfies the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within an extended period. This is a direct delisting risk disclosure under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T20:20:07.614474+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-08-26"}]}